Tdcp Adolescent and Adult is a vaccine being developed by
us for adolescents and adults (above 10 years old) that protects
against pertussis, containing slightly increased amount of TT
antigen to DTcP vaccine candidate for infants, but reduced
amounts of pertussis and DT antigens. We are developing a Tdcp
Adolescent and Adult candidate, which is a potential global best-in-class vaccine with a better formulation and immunogenicity compared to world-class vaccines such as Boostrix and Adacel. We expect to file a CTA for our Tdcp Adolescent and Adult candidate in EU by the end of 2018, and commence a phase I clinical trial in the EU in 2019. We plan to file a CTA in China by the end of 2020.
Copyright © ( 2017) CanSino Biologics Inc
For the record: 津ICP备14006666号-2